[HTML][HTML] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - hero.epa.gov
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology. Patients
present loss of lung function, dyspnea and dry cough. Diagnosis requires compatible …
present loss of lung function, dyspnea and dry cough. Diagnosis requires compatible …
[PDF][PDF] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - 2018 - academia.edu
Background: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC.
B Rindlisbacher, C Schmid, T Geiser… - Respiratory …, 2018 - search.ebscohost.com
Abstract < bold> Background: </bold> Idiopathic pulmonary fibrosis (IPF) is a lethal
lung disease of unknown etiology. Patients present loss of lung function, dyspnea and dry …
lung disease of unknown etiology. Patients present loss of lung function, dyspnea and dry …
[PDF][PDF] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - 2018 - core.ac.uk
Background: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser… - Respiratory …, 2018 - go.gale.com
Background Idiopathic pulmonary fibrosis (IPF) is a severe and progressive fibrosing
interstitial lung disease with sinister prognosis. The median survival is about 3-5 years after …
interstitial lung disease with sinister prognosis. The median survival is about 3-5 years after …
[引用][C] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - cir.nii.ac.jp
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic
pulmonary fibrosis – a potential biomarker role for LysoPC | CiNii Research CiNii 国立情報学 …
pulmonary fibrosis – a potential biomarker role for LysoPC | CiNii Research CiNii 国立情報学 …
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC.
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - europepmc.org
Background Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
[HTML][HTML] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis-a potential biomarker role for LysoPC.
B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - sonar.ch
METHOD The global metabolic profiles measured by ultra high-performance liquid
chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) of ten …
chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) of ten …